CTOs on the Move

OmniSYS

www.omnisys.com

 
OmniSYS is a technology company with 25+ years of experience working with pharmacies, payers, providers and pharmaceutical manufacturers. We leverage this unique market insight along with our pharmacy workflow expertise to deliver valuable solutions that help pharmacies thrive in the changing pharmacy landscape. Our solutions help pharmacies engage patients, grow clinical services and improve financial performance. OmniSYS currently serves over 25,000 pharmacies, connects to hundreds of payers and touches millions of patient lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.omnisys.com
  • 15950 Dallas Parkway Suite 350
    Dallas, TX USA 75248
  • Phone: 214.459.2574

Executives

Name Title Contact Details

Similar Companies

MindClick Partners Inc

MindClick Partners Inc is a West Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Public Health Institute

Public Health Institute is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Skin Authority

Skin Authority is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Affiliated Physicians

Affiliated Physicians is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.